{"nct_id":"NCT03776136","title":"Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004)","status":"COMPLETED","status_verified_date":"2024-09","start_date":"2019-01-30","start_date_type":"ACTUAL","primary_completion_date":"2023-10-11","primary_completion_date_type":"ACTUAL","completion_date":"2023-10-11","completion_date_type":"ACTUAL","phases":["PHASE2"],"tickers":["MRK"]}